Enleofen Bio is a biotechnology company that focuses on developing first-in-class antibody therapeutics for the treatment of fibrotic human diseases. Following the breakthrough discovery in the importance of interleukin 11 as a main driver of fibrosis, Enleofen was founded as a spin-out from National Heart Centre Singapore, SingHealth and Duke-NUS Medical School with Series A funding to translate research findings into treatme...
Enleofen Bio is a biotechnology company that focuses on developing first-in-class antibody therapeutics for the treatment of fibrotic human diseases. Following the breakthrough discovery in the importance of interleukin 11 as a main driver of fibrosis, Enleofen was founded as a spin-out from National Heart Centre Singapore, SingHealth and Duke-NUS Medical School with Series A funding to translate research findings into treatments that will improve and save the lives of millions of patients worldwide.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.